Development of novel therapy for malignant mesothelioma by controllingADCC activity.

恶性胸膜间皮瘤（malignant pleural mesothelioma， MPM）患者多有接触致癌石棉纤维的历史，本病潜伏期在40年以上。因此，患者的数量目前仍在增加。西妥昔单抗是一种针对EGFRand细胞外结构域的小鼠-人嵌合抗体，已被证明对结直肠癌和头颈癌有显著的疗效。然而，没有发表的体外或体内研究集中在西妥昔单抗对MPM的影响上。在本研究中，我们发现西妥昔单抗与增强其免疫功能和抗体依赖性细胞毒性（ADCC）活性的方法相结合，对MPM具有较强的抗肿瘤活性。我们的数据表明了ADCC活性在西妥昔单抗作用机制中的重要作用，并强调了西妥昔单抗作为一种新型治疗MPM的药物的潜力。

Most patients with malignant pleural mesothelioma (MPM) have a history of exposure to carcinogenic asbestos fibers, and the latent period of this disease is more than 40 years. Therefore, the numbers of the patients are now still increasing. Cetuximab is a chimeric mouse-human antibody directed against the extracellular domain of EGFRand has been shown remarkable effects for colorectal cancer and head and neck cancer. However, no published in vitro or in vivo studies have focused on the effect of cetuximab against MPM. In the present study, we found that cetuximab has potent anti-tumor activity against MPM in combination with the methods to enhance its immunological function, antibody-dependent cellular cytotoxicity (ADCC) activity. Our data indicate the important role of ADCC activity in the mechanism of action of cetuximab and underscore the promising potential of cetuximab as a new class of therapeutic agent for use against MPM.